Hosing C - Search Results

1

Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.

Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, Shaughnessy P, Snyder E, Bensinger W, Copelan E, Hosing C, Negrin R, Petersen FB, Rondelli D, Soiffer R, Leather H, Pazzalia A, Devine S. Giralt S, et al. Among authors: hosing c. Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013. Epub 2013 Oct 17. Biol Blood Marrow Transplant. 2014. PMID: 24141007 Free article. Review.

2

Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.

Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Körbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. Hosing C, et al. Ann Oncol. 2002 Mar;13(3):450-9. doi: 10.1093/annonc/mdf109. Ann Oncol. 2002. PMID: 11996478 Free article.

3

Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation.

Couriel DR, Beguelin GZ, Giralt S, De Lima M, Hosing C, Kharfan-Dabaja MA, Anagnostopoulos A, Champlin R. Couriel DR, et al. Among authors: hosing c. Bone Marrow Transplant. 2002 Oct;30(8):543-6. doi: 10.1038/sj.bmt.1703711. Bone Marrow Transplant. 2002. PMID: 12379897 Review.

4

Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications.

Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno N, Giralt S. Champlin R, et al. Among authors: hosing c. Oncology (Williston Park). 2003 Jan;17(1):94-100; discussion 103-7. Oncology (Williston Park). 2003. PMID: 12599934 Review.

5

Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.

Apisarnthanarax N, Donato M, Körbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini P. Apisarnthanarax N, et al. Among authors: hosing c. Bone Marrow Transplant. 2003 Mar;31(6):459-65. doi: 10.1038/sj.bmt.1703871. Bone Marrow Transplant. 2003. PMID: 12665841

6

Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.

Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, Cabanillas F, Champlin RE, Khouri IF. Hosing C, et al. Ann Oncol. 2003 May;14(5):737-44. doi: 10.1093/annonc/mdg200. Ann Oncol. 2003. PMID: 12702528 Free article.

7

Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab.

Wong R, de Lima M, Couriel D, Giralt S, Hosing C, Shahjahan M, Cheng YC, Bruton J, Champlin R, Khouri I. Wong R, et al. Among authors: hosing c. Leuk Lymphoma. 2003 May;44(5):829-32. doi: 10.1080/1042819031000067936. Leuk Lymphoma. 2003. PMID: 12802922

8

Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation.

Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, Forman AD, Kumar AJ, Champlin R, Couriel D. Wong R, et al. Among authors: hosing c. Br J Haematol. 2003 Jul;122(1):128-34. doi: 10.1046/j.1365-2141.2003.04447.x. Br J Haematol. 2003. PMID: 12823354 Free article.

9

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.

Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. Wong R, et al. Among authors: hosing c. Blood. 2003 Oct 15;102(8):3052-9. doi: 10.1182/blood-2003-03-0855. Epub 2003 Jul 3. Blood. 2003. PMID: 12842990 Free article.

10

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.

Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Ueno NT, et al. Among authors: hosing c. Blood. 2003 Nov 15;102(10):3829-36. doi: 10.1182/blood-2003-04-1022. Epub 2003 Jul 24. Blood. 2003. PMID: 12881308 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

301 results

Search Page